Thomas Lendvay
Thomas Lendvay previously served as Executive Officer and Director at Singletto Inc.
Recent coverage
Front-page news, podcasts and videos about Thomas
Seattle Startup Singletto Launches FDA-Approved Virus-Killing Masks on Amazon Following $10M Funding and DARPA Support
Seattle startup Singletto, with $10 million in funding and support from DARPA, has launched FDA-approved virus-neutralizing face masks on Amazon using its Oxafence Active Protection technology that kills 99.9% of certain viruses. The masks are the only FDA-cleared products in the U.S. that inactivate tested viruses and may have applications in healthcare and national security.
Seattle Startup Singletto Gains FDA Approval for Virus-Killing Oxafence Surgical Masks
Seattle startup Singletto received FDA approval for its Oxafence technology, a methylene blue-treated surgical mask that kills 99.9% of certain viruses within five minutes. The masks are already in use in New Zealand and represent a significant advancement over traditional masks by actively inactivating pathogens.
MicrobiomX raises $1M pre-seed to commercialize stool collection, processing and capsule-encapsulation device
Seattle startup MicrobiomX raised $1 million in a pre-seed round to develop a device that collects, processes and extrudes stool into capsules for clinical fecal microbiota transplantation and offers microbiome analysis services. The company, launched in 2020 from UW and Seattle Children’s Hospital research after a $50,000 CoMotion grant, aims to simplify messy current stool-processing methods used for FMT and autologous FMT.
Organizations
-
Singletto Executive Officer, Director 2020–present, Chief Medical Officer · current
